Varespladib (LY 315920), a specifically designed indolic secretory phospholipase A2 (sPLA2) inhibitor, has shown promising results in animals and adults. Inhibition seems to be inversely related to the severity of gas exchange impairment. Varespladib acts synergistically with pravastatin to decrease atherosclerosis, possibly through decreased levels of systemic inflammation or decreased lipid levels. Varespladib treatment also resulted in a profound increase in plasma PON activity and significantly larger fibrous caps, suggesting the formation of more stable plaque architecture.